Why Merck (MRK) Stock Is Falling In Pre-Market Trading Today

NEW YORK (TheStreet) -- Merck & Co. (MRK) shares are down -1.2% to $56.40 in pre-market trading after being downgraded to "equalweight" from "overweight" by analysts at Morgan Stanley  (MS) on Wednesday.

The downgrade comes on the heels of yesterday's news that German drug maker Bayer AG  (BAYRY) had agreed to purchase Merck's consumer care division for $14.2 billion.

The deal makes Bayer one of the largest over-the-counter drug companies in the world as it assumes control of Merck's most popular non-prescription brands.

Must Read: Warren Buffett's 10 Favorite Growth Stocks 

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.


MRK Chart

MRK data by YCharts

STOCKS TO BUY: TheStreet's Stocks Under $10 has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

If you liked this article you might like

Jim Cramer: These 4 Stocks Seem Attractive Right Here

Jim Cramer: These 4 Stocks Seem Attractive Right Here

The Jury Is Still Out on Merck

The Jury Is Still Out on Merck

Volatility Is Still in Charge: Cramer's 'Mad Money' Recap (Friday, 2/9/18)

Volatility Is Still in Charge: Cramer's 'Mad Money' Recap (Friday, 2/9/18)

Taking Merck's Temperature

Taking Merck's Temperature

Jim Cramer: These 4 Stocks Seem Attractive Right Here

Jim Cramer: These 4 Stocks Seem Attractive Right Here